Health and Fitness Health and Fitness
Thu, April 5, 2012
Wed, April 4, 2012
Tue, April 3, 2012
[ Tue, Apr 03rd 2012 ] - Market Wire
EntreMed Appoints Interim CEO
Mon, April 2, 2012
Sun, April 1, 2012
Sat, March 31, 2012
Fri, March 30, 2012
Thu, March 29, 2012
Wed, March 28, 2012
Tue, March 27, 2012
Mon, March 26, 2012
Sun, March 25, 2012
Sat, March 24, 2012
Fri, March 23, 2012
Thu, March 22, 2012
[ Thu, Mar 22nd 2012 ] - Market Wire
30 p.m. ET

Astex Pharmaceuticals to Present at AACR Annual Meeting


//health-fitness.news-articles.net/content/2012/ .. ceuticals-to-present-at-aacr-annual-meeting.html
Published in Health and Fitness on Thursday, March 29th 2012 at 3:40 GMT by Market Wire   Print publication without navigation


DUBLIN, Calif.--([ ])--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of fourteen abstracts for presentation at the American Association for Cancer Research (AACR) 2012 Annual Meeting. Oral and poster presentations will occur on March 31, April 1-3 in Chicago, IL.

Highlights include two oral presentations and two poster presentations on SGI-110, Astexas novel second generation DNMT inhibitor, and a poster presentation on new data from the first in class dual IAP inhibitor program:

Saturday, March 31, 2012

3:55 a" 4:30 pm CT

SGI-110

Invited Presentation
Scale-up and development of a process for a low-volume subcutaneous formulation of SGI-110, a potent hypomethylating agent

Monday, Apr 2, 2012

1:00 a" 5:00 pm CT

IAP

Poster Presentation, Abstract # 2018
Discovery of potent dual inhibitors of both XIAP and cIAP1 using fragment based drug discovery

Monday, Apr 2, 2012

3:00 a" 5:10 pm CT

SGI-110

Oral Presentation, Abstract #: LB-214
Interim results from a randomized Phase 1-2 first-in-human-(FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA) in relapsed/refractory MDS and AML

Tuesday, Apr 3, 2012

1:00 a" 5:00 pm CT

SGI-110

Poster Presentation, Abstract # 4077
Chemosensitizing effects of the novel, small molecule DNA methylation inhibitor SGI-110 in ovarian cancer

Tuesday, Apr 3, 2012

1:00 a" 5:00 pm CT

SGI-110

Poster Presentation, Abstract # 4076
SGI-110, a novel subcutaneous (SQ) second generation DNA hypomethylating agent achieves improved pharmacodynamics (PD), safety and pharmacokinetics (PK) in comparison to IV decitabine in a non-human primate in vivo study

Nine additional presentations will highlight new data on the companyas drug development programs with AT13387 (HSP90 inhibitor), AT9283 (JAK/Aurora inhibitor), AT13148 (AGC Kinase inhibitor), MetAP2 inhibitors, PKM2 (Pyruvate Kinase) activators, and second generation PIM Kinase inhibitors. Select posters will be made available for viewing on the companyas website [ www.astx.com ] following the public presentation.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit [ http://www.astx.com ].


Publication Contributing Sources